title: Effective treatment of anemia in pediatric kidney transplant recipients with methoxy polyethylene glycol-epoetin beta.
abstract: MPG-EPO is a continuous erythropoietin receptor activator with a longer half-life than darbepoetin, hence requires less frequent injections. It has been successfully used in adults, but currently, there are no published data available for its use in children. This pilot study was performed to verify the effect of MPG-EPO on Hb levels in children. Twelve patients (age 6.4-17.2 yr) were treated with MPG-EPO as an individual "Heilversuch" according to German law after RTx. Five patients were switched from DA, and seven were naïve to erythropoietin. Over a period of six months, Hb levels were measured monthly. A median MPG-EPO dose of 2.5 μg/kg was administered intravenously in a single dose every four wk. The median Hb value increased in naïve patients from 9.9 to 11.2 g/dL (median, p = 0.004) and from 10.3 to 11.6 g/dL (median, p = 0.39) in patients switched from DA to MPG-EPO. No adverse events secondary to MPG-EPO therapy were detected. Our results indicate that a once-monthly injection of MPG-EPO is an effective treatment of anemia in children after renal transplantation. Larger randomized trials will have to confirm our findings.
authors.affiliation: Clinic of Pediatric Kidney-, Liver- and Metabolic Diseases, Children's Hospital, Hannover Medical School, Hannover, Germany.
authors.forename: Mirja
authors.initials: M
authors.lastname: Wedekin
authors.forename: Jochen H H
authors.initials: JH
authors.lastname: Ehrich
authors.forename: Lars
authors.initials: L
authors.lastname: Pape
mesh_terms: D000293:Adolescent; D000740:Anemia / Q000188:drug therapy* / Q000209:etiology*; D002648:Child; D004337:Drug Carriers / Q000627:therapeutic use; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D005293:Ferritins / Q000097:blood; D005919:Glomerular Filtration Rate; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000379:methods*; D008297:Male; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011183:Postoperative Complications; D011994:Recombinant Proteins; D014168:Transferrin / Q000096:biosynthesis; D016896:Treatment Outcome
chemical_list: D004337:Drug Carriers; D007166:Immunosuppressive Agents; D011994:Recombinant Proteins; D014168:Transferrin; C103998:epoetin beta; D004921:Erythropoietin; D011092:Polyethylene Glycols; C028210:monomethoxypolyethylene glycol; D005293:Ferritins